20405 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines Morphinan derivatives, e.g. morphine, codeine
Gastric retentive extended release pharmaceutical compositions
#2702Abuse-resistant formulations
#2703TAMPER RESISTANT IMMEDIATE RELEASE FORMULATIONS
#2704Methods of increasing satellite cell proliferation
#2705PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
#2706Extended Release Compositions Comprising Hydrocodone And Acetaminophen For Rapid Onset And Prolonged Analgesia That May Be Administered Without Regard To Food
#27078-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
#2708Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
#2709ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
#2710ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
#2711ORALLY ADMINISTRABLE, SELF-SUPPORTING DISSOLVING FILM DOSAGE FORMS
#2712Compositions with a rheological modifier to reduce dissolution variability
#2713Compositions of a polyorthoester and an aprotic solvent
#2714Morphine formulations
#2715Compositions Comprising An Opioid And An Additional Active Pharmaceutical Ingredient For Rapid Onset And Extended Duration Of Analgesia That May Be Administered Without Regard To Food
#2716Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
#2717Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain
#2718Compositions of a polyorthoester and an aprotic solvent
#2719Abuse deterrent compositions and methods of use
#2720ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
#2721Abuse deterrent compositions and methods of use
#2722Tamper resistant pharmaceutical formulations
#2723High drug load buprenorphine microspheres and method of producing same
#2724Sustained release formulation of nalbuphine
#2725Abuse deterrent solid dosage form for immediate release with functional score
#2726Abuse-deterrent dosage forms
#2727Controlled release hydrocodone formulations
#2728Abuse resistant capsule
#2729Sublingual and buccal film compositions
#2730SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
#2731METHODS AND DEVICE FOR TREATING OPIOID ADDICTION
#2732METHODS AND DEVICE FOR TREATING OPIOID ADDICTION
#2733Tamper resistant dosage form comprising an adsorbent and an adverse agent
#2734Pain medicine combination and uses thereof
#2735Drug combinations and uses in treating a coughing condition
#2736Drug combinations and uses in treating a coughing condition
#2737Methods of delivering pharmaceutical agents
#2738Glutamate agents in the treatment of mental disorders
#2739INTRANASAL NALTREXONE
#2740Oral formulations and lipophilic salts of methylnaltrexone
#2741Parenteral formulations of dopamine agonists
#2742Misuse preventative, controlled release formulation
#2743Abuse resistant forms of extended release morphine, method of use and method of making
#2744Abuse resistant forms of extended release morphine, method of use and method of making
#2745Enhanced stability of novel liquid compositions
#2746METHODS AND COMPOSITIONS FOR TREATING ANXIETY DISORDERS OR SYMPTOMS THEREOF
#2747ADENINE DERIVATIVES HAVING IMMUNOMODULATING ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY
#2748Stable pharmaceutical formulations of methylnaltrexone
#2749Buprenorphine for the treatment of acute suicidality
#2750Combination of pilocarpin and methimazol for treating Charcot-Marietooth disease and related disorders
#2751Anise flavored medication
#2752Pharmaceutical formulation containing gelling agent
#2753DRY POWDER COMPOUND FORMULATIONS AND USES THEREOF
#2754Tamper resistant pharmaceutical formulations
#2755Method of treating dyskinesia
#2756PREOPERATIVE TREATMENT OF POST OPERATIVE PAIN
#2757USE OF OPIOID ANTAGONISTS FOR TREATING URINARY RETENTION
#2758Reduction of opioid blood fluctuations
#2759Abuse-deterrent pharmaceutical compositions for controlled release
#2760ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
#2761ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
#2762Pharmaceutical Formulation Containing Gelling Agent
#2763METHODS FOR TREATING EYE DISORDERS USING OPIOID RECEPTOR ANTAGONISTS
#2764Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
#2765Opioid prodrugs with heterocyclic linkers
#2766Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
#2767Opioid agonist/antagonist combinations
#2768Controlled release hydrocodone
#2769Carboxamide bioisosteres of opiates
#2770Abuse-resistant controlled-release opioid dosage form
#2771OXIDATION-STABILIZED TAMPER-RESISTANT DOSAGE FORM
#2772ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS
#2773Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
#2774Opioid dosage forms having dose proportional steady state Cand AUC and less than dose proportional single dose C
#2775GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC
#2776ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS
#2777Extended buprenorphine transdermal delivery compositions and methods for using the same
#2778ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER
#2779Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
#2780METHODS FOR TREATING PRURITUS
#2781Non-mucoadhesive film dosage forms
#2782Compositions for treating CMT and related disorders
#2783Methods and compositions for treatment of epithelial wounds
#2784Methods for treating pruritus
#2785INTRANASAL NALTREXONE
#2786TREATMENT OF ANTIFOLATE NEUROTOXICITY
#2787Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
#2788Method for treating a GD2 positive cancer
#2789ABUSE-PROOFED DOSAGE FORM
#2790Oral pharmaceutical dispersion compositions
#2791Treatment with opioid antagonists and mTOR inhibitors
#2792Compositions comprising enzyme-cleavable oxycodone prodrug
#2793Pharmaceutical formulation containing irritant
#2794Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
#2795NALTREXONE LONG ACTING FORMULATIONS AND METHODS OF USE
#2796Use of amisulpride as an anti-emetic
#2797MODULATION OF CELL BARRIER DYSFUNCTION
#2798LONG-ACTING INJECTABLE ANALGESIC FORMULATIONS FOR ANIMALS
#2799Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist
#2800Abuse-resistant controlled-release opioid dosage form
#2801OXYMORPHONE CONTROLLED RELEASE FORMULATIONS
#2802PHARMACEUTICAL COMPOSITIONS
#2803NUTRITIONAL SUPPLEMENT COMPOSITIONS
#2804COMBINATION OF AN ANTIPSYCHOTIC AND AN ANTI-INFLAMMATORY AGENT
#2805Composition and use for phosphodiesterase inhibitors
#2806Dendrimer conjugates
#2807Methods and compositions for treating anxiety disorders or symptoms thereof
#2808Modified release formulations containing drug-ion exchange resin complexes
#2809Analgesic pharmaceutical composition for oral administration
#2810ABUSE RESISTANT DRUG FORMS
#2811Abuse-deterrent drug formulations
#2812Polymer release system
#2813ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION
#2814PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM
#2815Morphinan compounds
#2816Class of non-stimulant treatment and ADHD and related disorders
#2817ABUSE-PROOFED ORAL DOSAGE FORM
#2818Crush resistant delayed-release dosage forms
#2819Controlled release hydrocodone formulations
#2820ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS
#2821Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form
#2822Abuse-resistant controlled-release opioid dosage form
#2823Compositions for drug administration
#2824Method for administering omega-conopeptide
#2825Abuse-deterrent pharmaceutical compositions of opioids and other drugs
#2826Gastric retentive extended release pharmaceutical compositions
#2827ABUSE-PROOFED DOSAGE FORM
#2828DRUG DETOXIFICATION PROTOCOL USING MICRODOSING
#2829Tamper-resistant oral opioid agonist formulations
#2830BENZAZOCINE-RING COMPOUND INHIBITION OF TAU HYPERPHOSPHORYLATION
#2831TAMPER RESISTANT DOSAGE FORMS
#2832Morphine polymer release system
#2833ABUSE-PROOFED DOSAGE FORM
#2834Implantable Polymeric Device for Sustained Release of Buprenorphine
#2835Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
#2836Buprenorphine transdermal therapeutic system and method of administering
#2837Abuse-proofed dosage forms
#2838METHODS FOR PROPHYLATIC APPETITE SUPPRESSION
#2839Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
#28408-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
#2841Peripheral opioid receptor antagonists and uses thereof
#2842Two-component pharmaceutical composition for the treatment of pain
#2843Particulate materials
#2844Crush resistant delayed-release dosage forms
#2845Combination dopamine antagonist and opiate receptor antagonist treatment of addictive behavior
#2846METHOD OF PROVIDING SUSTAINED ANALGESIA WITH BUPRENORPHINE
#2847Pharmaceutical composition and methods for peptide treatment
#2848ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM
#2849Use of opioid antagonists to attenuate endothelial cell proliferation and migration
#2850Methylnaltrexone nasal formulations, methods of making, and use thereof
#2851OPIOIDS FOR THE TREATMENT OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
#2852Controlled Release Pharmaceutical Dosage Forms
#2853Pharmaceutical Composition
#2854Permeant delivery system and methods for use thereof
#2855Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan
#2856Pharmaceutical compositions resistant to abuse
#2857PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
#2858Matrix for sustained, invariant and independent release of active compounds
#2859PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE
#2860PRAMIPEXOLE TRANSDERMAL DELIVERY FOR SEVERE HEADACHES
#2861CONTROLLED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS
#2862COMBINATION OF AN OPIOID AGONIST AND AN OPIOID ANTAGONIST IN THE TREATMENT OF PARKINSON'S DISEASE
#2863Pharmaceutical Composition
#2864DOSAGE FORM CONTAINING OXYCODONE AND NALOXONE
#2865Tamper resistant dosage forms
#28663-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
#2867Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
#2868Modified release formulations containing drug-ion exchange resin complexes
#2869TAMPER RESISTANT DOSAGE FORMS
#2870Pharmaceutical compositions
#2871TAMPER RESISTANT DOSAGE FORMS
#2872NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
#2873Extended release, abuse deterrent pharmaceutical compositions
#2874Encased tamper resistant controlled release dosage forms
#2875Use of opioid antagonists
#2876Encased tamper resistant controlled release dosage forms
#2877Abuse deterrent pharmaceutical compositions for controlled release
#2878Abuse and alcohol resistant drug composition
#2879Intrathecal hydromorphone solutions having improved stability
#2880SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
#2881Nalmefene for reduction of alcohol consumption in specific target populations
#2882Nalmefene for reduction of alcohol consumption in specific target populations
#2883Selective opioid compounds
#2884ORAL PHARMACEUTICAL DISPERSION COMPOSITIONS
#2885Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
#2886Anti-nausea drug combinations
#2887Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
#2888FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS
#2889TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS
#2890REDUCING SIDE EFFECTS OF TRAMADOL
#2891Oral Pharmaceutical Dosage Forms
#2892Oral pharmaceutical dosage forms
#2893Transdermal therapeutic system comprising buprenorphine
#2894Oral formulations and lipophilic salts of methylnal trexone
#2895USE OF SIGMA LIGANDS IN BONE CANCER PAIN
#2896SYNTHESIS OF R-N-METHYLNALTREXONE
#2897Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
#2898METHODS FOR TREATMENT AND PREVENTION OF OPIOID INDUCED CONSTIPATION USING ORAL COMPOSITIONS OF METHYLNALTREXONE
#2899Methods Useful for the Treatment of Pain, Arthritic Conditions or Inflammation Associated with a Chronic Condition
#2900Morphinan compounds
#2901Therapeutic or prophylactic agent for cachexia
#2902Abuse-deterrent drug formulations
#2903Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
#2904Morphine and morphine precursors
#2905Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#29065-methyl-1-(naphthalen-2-yl)-1H-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
#2907Pharmaceutical formulation containing gelling agent
#2908Controlled release hydrocodone formulations
#2909Compositions and Methods for Prophylaxis and Treatment of Addictions
#2910Controlled release hydrocodone
#2911Oral drug delivery system
#2912Compositions for deterring abuse of opioid containing dosage forms
#2913Methods and compositions to prevent addiction
#2914Formulations and methods for the controlled release of active drug substances
#2915Oral drug delivery system
#2916SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
#2917Oral drug delivery system
#2918SUSTAINED RELEASE MONOEXIMIC FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS
#2919Opioid agonist antagonist combinations
#2920Soft Elastic Capsules Containing Tablets and Liquid or Semisolid Fills and Methods for Their Manufacture
#2921Immediate release, abuse deterrent pharmaceutical compositions
#2922COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN
#2923Sustained-release polymeric microparticles containing poorly water-soluble drug and method for preparing the same
#2924Oral film containing opiate enteric-release beads
#2925Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
#2926Treatment of addiction and impulse-control disorders using PDE7 inhibitors
#2927Long acting dual release product containing carbinoxamine and pseudoephedrine
#2928Pharmaceutical formulation containing gelling agent
#2929Pharmaceutical formulation containing gelling agent
#2930Pharmaceutical formulation containing gelling agent
#2931Tamper resistant dosage forms
#2932Controlled release dosage forms
#2933Tamper resistant dosage forms
#2934Tamper resistant dosage forms
#2935TAMPER RESISTANT DOSAGE FORMS
#2936Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
#2937METHODS FOR REDUCING BINGE OR COMPULSIVE EATING
#2938Tamper resistant dosage forms
#2939TAMPER RESISTANT DOSAGE FORMS
#2940TAMPER RESISTANT DOSAGE FORMS
#2941Tamper resistant dosage forms
#2942Tamper resistant dosage forms
#2943Tamper-resistant oral opioid agonist formulations
#2944ABUSE-PROOFED ORAL DOSAGE FORM
#2945Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
#2946INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY
#2947Pharmaceutical formulation containing gelling agent
#2948USE OF BINDERS FOR MANUFACTURING STORAGE STABLE FORMULATIONS
#2949Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
#2950Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
#2951SUSTAINED RELEASE COMPOSITION COMPRISING AN AMINE AS ACTIVE AGENT AND A SALT OF A CYCLIC ORGANIC ACID
#2952Stability of hydromorphone hydrochloride solutions
#2953SILICONE COATED IMPLANT
#2954Abuse-resistant oral dosage forms and method of use thereof
#2955Self-destructing transdermal therapeutic system having improved functionality and efficacy
#2956DEXTROMETHORPHAN ANTITUSSIVE COMPOSITIONS
#2957Sublingual films
#2958Method of restoring the incretin effect
#2959Method and Device for assistance in delivery of medication, and Formulas
#2960Pharmaceutical formulation containing gelling agent
#2961Injectable flowable composition comprising buprenorphine
#2962Pharmaceutical compositions
#2963Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
#2964Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
#2965ABUSE-RESISTANT OPIOID DOSAGE FORM
#2966ABUSE-RESISTANT FORMULATIONS
#2967CONTROLLED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS
#2968Therapeutic or prophylactic agent for biliary diseases
#2969Injectable flowable composition comprising buprenorphine
#2970Compositions comprising buprenorphine
#2971Combination of active loaded granules with additional actives
#2972Parenteral formulations of dopamine agonists
#2973Methods for treatment of pain
#2974Substituted cellulose acetates and uses thereof
#2975Non-abusable pharmaceutical composition comprising opioids
#2976Non-abusable pharmaceutical composition comprising opioids
#2977PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE DISORDERS
#2978HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY
#2979Heterogeneous implantable devices for drug delivery
#2980ABUSE-PROOFED DOSAGE FORM
#2981METHODS OF TREATING PAIN AND MORPHINE TOLERANCE VIA MODULATION OF HEDGEHOG SIGNALLING PATHWAY
#2982ADMINISTRATION OF INTRAVENOUS IBUPROFEN TO TRAUMA PATIENTS
#2983METHOD OF REDUCING CNS AND GASTROINTESTINAL SIDE AFFECTS ASSOCIATED WITH LONG-TERM, DEXTROMETHORPHAN/LOW-DOSE QUINIDINE COMBINATION THERAPY
#2984Compositions and methods for minimizing or reversing agonist-induced desensitization
#2985Compositions of buprenorphine and μ antagonists
#2986HIGH BIOAVAILABILITY OPIOID FORMULATIONS
#2987Heterogeneous implantable devices for drug delivery
#2988Pharmaceutical compositions comprising hydromorphone and naloxone
#2989ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER
#2990Method of treating atherogenic dyslipidemia
#2991TOPICAL PERIPHERAL NEURO-AFFECTIVE (TPNA) THERAPY
#2992Manufacturing of active-free granules and tablets comprising the same
#2993Opioid agonist/opioid antagonist/acetaminophen combinations
#29948-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
#2995METHOD OF DRUG DETOXIFICATION
#2996Solubilization and bioavailability of acetaminophen
#2997Amphipathic lipid-based sustained release compositions
#2998USE OF A COMBINATION OF AN OPIOID AGONIST AND AN OPIOID ANTAGONIST FOR THE TREATMENT OF CROHN'S DISEASE AND THE SYMPTOMS ASSOCIATED WITH CROHN'S DISEASE
#2999PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS
#3000Compositions and methods for delivery of poorly soluble drugs